熱門資訊> 正文
Innate Pharma GAAP每股收益为-0.31欧元,收入为1,235万欧元
2024-09-12 13:15
- Innate Pharma press release (NASDAQ:IPHA): 1H GAAP EPS of -€0.31.
- Revenue of €12.35M (-69.3% Y/Y).
- Cash position of €102.1 million as of June 30, 2024, anticipated cash runway to end of 2025.
More on Innate Pharma:
- Innate falls on updated phase 1/2 data on blood cancer asset teamed with Sanofi
- Seeking Alpha’s Quant Rating on Innate Pharma
- Historical earnings data for Innate Pharma
- Financial information for Innate Pharma
- Historical earnings data for Innate Pharma S.A.
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。